U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07357519) titled 'Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)' on Jan. 14.
Brief Summary: This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
Study Start Date: Dec. 31, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed / Refractory Osteosarcoma
Intervention:
DRUG: LNTH2403 Phase 1 dose
LNTH-2403 administered once every 8 weeks, with the potential to explore other dosing schedules based on obser...